$27.45
-3.96 (-12.61%)
Open$30.86
Previous Close$31.41
Day High$32.07
Day Low$27.01
52W High$45.50
52W Low$4.97
Volume—
Avg Volume682.7K
Market Cap230.94M
P/E Ratio—
EPS$-26.99
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
-42.6% upside
Current
$27.45
$27.45
Target
$15.75
$15.75
$10.91
$15.75 avg
$18.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 63.96M | 17.68M | 17.52M |
| Net Income | -61,945,321 | -69,679,191 | -1,532,650 |
| Profit Margin | -96.9% | -416.1% | -8.8% |
| EBITDA | -61,046,135 | -74,344,734 | -1,913,244 |
| Free Cash Flow | — | — | -1,533,941 |
| Rev Growth | +180.1% | -14.7% | +0.6% |
| Debt/Equity | — | 0.25 | 1.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |